Fulcrum Therapeutics (FULC) AI Stock Analysis

• Market Cap: $498.72M
• Dividend Yield: N/A
• Average Volume (3M): 501.71K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.52
• Revenue Growth: -100.00%
• EPS Growth: -266.37%
• Country: US
• Employees: 45
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.28
• Shares Outstanding: 54,091,587
• 10 Day Avg. Volume: 395,939
• 30 Day Avg. Volume: 501,706
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: 0.45
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: -2.74
• 1Y Price Target: $12.17
• Price Target Upside: 35.98% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 6

• Rating: 60 Neutral
• Price Target: $9.50 ▲(6.15% Upside)

Fulcrum Therapeutics' stock score is primarily driven by its strong technical momentum and robust balance sheet, despite challenges in profitability and valuation. The company's ability to leverage its financial strength for future growth is crucial.

Positive Factors

Robust Balance Sheet

A strong balance sheet with high equity and minimal debt provides financial stability and flexibility, supporting long-term growth initiatives.

Cash Flow Improvement

Improved cash flow management indicates better operational efficiency, enhancing the company's ability to fund R&D and strategic investments.

Strong Gross Profit Margin

A high gross profit margin reflects effective cost management, which can support profitability as the company scales its operations.

Negative Factors

Negative Net Income

Persistent negative net income highlights challenges in achieving profitability, which may impact long-term financial sustainability.

Significant Operating Losses

High operating losses suggest inefficiencies that need addressing to improve profitability and ensure sustainable growth.

Uncertain Cash Flow Stability

Uncertainty in cash flow stability could hinder future investment and operational capabilities, affecting long-term growth prospects.

Fulcrum Therapeutics Business Overview & Revenue Model

Company Description

Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy; and FTX-6058, an investigational oral fetal hemoglobin inducer for the treatment of sickle cell disease and other hemoglobinopathies, including beta-thalassemia. The company is also discovering drug targets for the treatments of rare neuromuscular, muscular, central nervous system, and hematologic disorders, as well as cardiomyopathies and pulmonary diseases. Fulcrum Therapeutics, Inc. has research and discovery collaboration agreement with Acceleron Pharma Inc. to identify biological targets to modulate specific pathways associated with a targeted indication within the pulmonary disease space; and has a strategic collaboration and license agreement with MyoKardia, Inc. to discover, develop, and commercialize novel targeted therapies for the treatment of genetic cardiomyopathies. Fulcrum Therapeutics, Inc. was Incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

How the Company Makes Money

Fulcrum Therapeutics generates revenue primarily through the development and commercialization of its therapeutic products. The company may earn money through various channels, including partnerships with larger pharmaceutical companies that provide funding for research and development in exchange for a share in future profits. Additionally, Fulcrum can benefit from milestones and royalties associated with the successful advancement of its drug candidates through clinical trials and regulatory approvals. Other potential revenue sources include licensing agreements for its proprietary technologies and intellectual property, as well as government grants and research funding aimed at supporting innovative therapeutic research.

Fulcrum Therapeutics Financial Statement Overview

Summary

Fulcrum Therapeutics has a strong gross profit margin and a robust balance sheet with low leverage. However, the company faces challenges with operational profitability and cash flow sustainability due to consistent net losses.

Income Statement

Fulcrum Therapeutics shows a stable revenue over the TTM period with $80M, but the company is struggling with negative net income at -$510,000 and a significant negative EBIT margin of -15.58%. The company's gross profit margin is strong at 78.42%, indicating good cost control over production, but the high operating losses need addressing to improve profitability.

Balance Sheet

The balance sheet of Fulcrum Therapeutics is robust, with a high equity ratio of 94.15% and low debt-to-equity ratio of 0.04, indicating minimal reliance on debt. The company's stockholders' equity stands strong at $228.49M, providing a solid financial foundation. However, the company needs to focus on converting this equity strength into operational profitability.

Cash Flow

Fulcrum Therapeutics shows improvement in cash flow with a positive operating cash flow of $7.81M in the TTM period, turning around from previous negative cash flows. The free cash flow is also positive at $7.56M, indicating better cash management. However, the operating cash flow to net income ratio is not sustainable at 15.31 due to negative net income, which suggests future cash flow stability is uncertain.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	0.00	80.00M	2.81M	6.34M	19.16M	8.82M
Gross Profit	0.00	78.41M	2.81M	3.93M	16.65M	6.44M
EBITDA	-81.62M	-18.24M	-108.49M	-109.72M	-78.54M	-69.23M
Net Income	-73.22M	-9.72M	-97.33M	-105.62M	-78.33M	-68.44M
Balance Sheet
Total Assets	228.84M	260.72M	257.69M	226.69M	235.00M	129.58M
Cash, Cash Equivalents and Short-Term Investments	214.11M	241.02M	236.22M	202.92M	218.16M	112.91M
Total Debt	7.57M	8.63M	10.82M	13.42M	0.00	17.00K
Total Liabilities	14.46M	17.68M	22.50M	27.74M	23.46M	34.40M
Stockholders Equity	214.38M	243.03M	235.19M	198.94M	211.54M	95.18M
Cash Flow
Free Cash Flow	-65.22M	-2.50M	-91.47M	-99.01M	-80.19M	-55.00M
Operating Cash Flow	-64.91M	-2.22M	-90.97M	-97.05M	-78.48M	-53.66M
Investing Cash Flow	19.77M	32.23M	-36.69M	12.41M	-129.67M	-57.14M
Financing Cash Flow	1.02M	2.75M	118.12M	84.32M	186.51M	71.13M

Fulcrum Therapeutics Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 8.95
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For FULC, the sentiment is Neutral. The current price of 8.95 is below the 20-day moving average (MA) of 9.20, above the 50-day MA of 7.89, and above the 200-day MA of 5.79, indicating a neutral trend. The MACD of 0.34 indicates Positive momentum. The RSI at 52.30 is Neutral, neither overbought nor oversold. The STOCH value of 54.17 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for FULC.

Fulcrum Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
FULC	60 Neutral	$498.72M	―	-30.00%	―	-100.00%	-266.37%
ADCT	56 Neutral	$464.62M	―	―	―	15.73%	38.73%
GLUE	52 Neutral	$592.27M	27.25	9.81%	―	2990.57%	―
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
MNPR	48 Neutral	$559.42M	―	-59.38%	―	―	-66.95%
INBX	46 Neutral	$553.63M	0.20	-113.71%	―	―	―
OPT	39 Underperform	$480.62M	―	―	―	-80.09%	60.14%

Fulcrum Therapeutics Corporate Events

Fulcrum Therapeutics Highlights Progress in Sickle Cell Treatment

On August 28, 2025, Fulcrum Therapeutics released an updated corporate presentation highlighting their progress and strategic focus on developing treatments for genetically defined rare diseases. The presentation emphasized the potential of pociredir in treating sickle cell disease, showcasing promising results from their Phase 1b PIONEER study, which demonstrated significant increases in fetal hemoglobin and improvements in key markers of hemolysis. These developments position Fulcrum as a key player in addressing the unmet needs in the SCD treatment landscape, despite recent challenges faced by other therapies in the market.

The most recent analyst rating on (FULC) stock is a Hold with a $6.50 price target. To see the full list of analyst forecasts on Fulcrum Therapeutics stock, see the FULC Stock Forecast page.

Fulcrum Therapeutics Reports Q2 2025 Financial Results

Fulcrum Therapeutics, Inc., a biotechnology company based in Cambridge, Massachusetts, focuses on developing small molecules for genetically-defined rare diseases with high unmet medical needs. In its latest earnings report for the quarter ended June 30, 2025, Fulcrum Therapeutics reported a net loss of $17.3 million, a significant shift from the $55.4 million net income in the same period last year, primarily due to the absence of collaboration revenue. The company’s operating expenses decreased to $19.8 million from $27.5 million, reflecting a reduction in research and development as well as general and administrative costs. Despite the financial loss, Fulcrum maintains a strong cash position with $42.6 million in cash and cash equivalents and $171.5 million in marketable securities, which the company believes will fund its operations for at least the next 12 months. Looking forward, Fulcrum Therapeutics remains committed to advancing its clinical trials and research programs, with a focus on its lead product candidate, pociredir, and exploring strategic opportunities to enhance its pipeline and financial standing.

Fulcrum Therapeutics Announces Promising Phase 1b Trial Results

On July 29, 2025, Fulcrum Therapeutics announced promising results from the 12 mg dose cohort of its Phase 1b clinical trial of pociredir for sickle cell disease. The trial showed significant increases in fetal hemoglobin and improvements in key markers of hemolysis and anemia, with pociredir being well-tolerated and no serious adverse events reported. These findings suggest potential benefits in reducing vaso-occlusive crises and improving patient outcomes, positioning Fulcrum favorably in the biopharmaceutical industry. The company also reported a cash runway into 2028, despite a net loss in the second quarter of 2025.

The most recent analyst rating on (FULC) stock is a Hold with a $4.00 price target. To see the full list of analyst forecasts on Fulcrum Therapeutics stock, see the FULC Stock Forecast page.